

In the Specification

Please amend paragraph [0012] of the specification as published as follows:

The present invention is based on the inventors findings, that human transketolase like-1 gene as given in SEQ[[.]] ID[[.]] NO: 1 (cf. TKT-L1, TKR: NM.sub.--012253; Accession number: X91817) is highly overexpressed in tissue of colon carcinoma, pancreatic carcinoma, lung cancer and gastric cancer compared to the level found in respective normal control tissue. This is especially valuable for diagnostic purposes, as transketolase enzyme is not comparably overexpressed in tumour tissue.

Please amend paragraph [0022] of the specification as published as follows:

FIG. 7: DNA (SEQ ID NO: 1) and amino acid sequence (SEQ ID NO: 2) of tktl1; the part of the protein being used for the immunization for antibody generation is given in bold letters (SEQ ID NO: 3); additionally peptides are underlined which were used for peptide immunization for antibody generation (SEQ ID NOS: 4 and 5).

Please amend paragraph [0153] of the specification as published as follows:

[0153] PCR reactions are performed in 25 .mu.l volumes with a final concentration of 300 nmol for each primer, with 95.degree. C. for 15 sec and 60.degree. C. for 60 sec, for 40 cycles. The following primers are used for quantitative PCR:

2 Transketolase like-1: Primer A (SEQ ID NO: 6): CACCTTGGGATTCTGTGTGC Primer B (SEQ ID NO: 7): TCTCATCACAAAGCAGCACAG Transketolase: Primer A (SEQ ID NO: 8): TGTGTCCAGTGCAGTAGTGG Primer B (SEQ ID NO: 9): ACACATTCATAACCGCCCTAG

Please insert after paragraph [0164] but before the claims the following statement:

The electronically submitted text file entitled "SEQUENCE_LISTING" created March 8, 2007 and having a size of 12 KB is incorporated by reference.